drugset / Trial / NCT01864538
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
Timeline
- Start
- 2013-05
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evofosfamide | Other / unclassified | 480 mg/m2 | Intravenous |